IV 
118TH CONGRESS 
1ST SESSION 
H. RES. 425 
Supporting the designation of July 19, 2023, as ‘‘Glioblastoma Awareness 
Day’’. 
IN THE HOUSE OF REPRESENTATIVES 
MAY 18, 2023 
Mr. MAST (for himself, Ms. SCHAKOWSKY, Mr. GALLAGHER, and Mr. 
AUCHINCLOSS) submitted the following resolution; which was referred to 
the Committee on Energy and Commerce 
RESOLUTION 
Supporting the designation of July 19, 2023, as 
‘‘Glioblastoma Awareness Day’’. 
Whereas approximately 14,490 new cases of glioblastoma will 
be diagnosed in the United States in 2023; 
Whereas glioblastoma is— 
(1) the most common malignant (cancerous) brain 
tumor, accounting for approximately 1⁄2 of all primary 
malignant brain tumors; and 
(2) the most aggressive, complex, difficult to treat, 
and deadly type of brain tumor; 
Whereas it is estimated that more than 10,000 individuals in 
the United States will succumb to glioblastoma each year; 
VerDate Sep 11 2014 
02:07 May 19, 2023
Jkt 039200
PO 00000
Frm 00001
Fmt 6652
Sfmt 6300
E:\BILLS\HR425.IH
HR425
pbinns on DSKJLVW7X2PROD with $$_JOB
•HRES 425 IH 
Whereas the 5-year survival rate for glioblastoma patients is 
only 6.9 percent, and the median length of survival for 
glioblastoma patients is only 8 months; 
Whereas glioblastoma is described as a disease that affects 
the ‘‘essence of self’’, as the treatment and removal of 
glioblastoma presents significant challenges due to the 
uniquely complex and fragile nature of the brain, the pri-
mary organ in the human body that controls not only 
cognitive ability, but also the actions of every organ and 
limb; 
Whereas patients and caregivers play a critical role in fur-
thering research for glioblastoma; 
Whereas, relative to other types of cancers, brain cancer pa-
tients pay the second highest out-of-pocket costs for med-
ical services in both the initial and end-of-life phases of 
care; 
Whereas, although research advances may fuel the develop-
ment of new treatments for glioblastoma, challenging ob-
stacles to accelerating progress toward new treatments 
for glioblastoma remain, and there are no screening or 
early detection methods; 
Whereas, in 2021, the World Health Organization reclassified 
brain tumors and made significant changes to the molec-
ular characteristics of a glioblastoma diagnosis, necessi-
tating critical biomarker testing for patients suspected of 
having a possible glioblastoma; 
Whereas, although glioblastoma was first described in medical 
and scientific literature in the 1920s, and despite its dev-
astating prognosis, only 4 drugs and 1 medical device 
have been approved by the Food and Drug Administra-
tion to specifically treat glioblastoma since the 1920s, 
VerDate Sep 11 2014 
02:07 May 19, 2023
Jkt 039200
PO 00000
Frm 00002
Fmt 6652
Sfmt 6300
E:\BILLS\HR425.IH
HR425
pbinns on DSKJLVW7X2PROD with $$_JOB
•HRES 425 IH 
term prognosis for, and the quality of life of, individ-
uals diagnosed with the disease; 
(5) recognizes the importance of molecular bio-
marker testing to the diagnosis and treatment of 
glioblastoma; 
(6) expresses support for the individuals who 
are battling brain tumors, as well as the families, 
friends, and caregivers of those individuals; 
(7) urges a collaborative approach to brain 
tumor research among governmental, private, and 
nonprofit organizations, which is a promising means 
of advancing the understanding and treatment of 
glioblastoma; and 
(8) encourages continued investments in glio-
blastoma research and treatments, including through 
the Glioblastoma Therapeutics Network and other 
existing brain tumor research resources. 
Æ 
VerDate Sep 11 2014 
02:07 May 19, 2023
Jkt 039200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6301
E:\BILLS\HR425.IH
HR425
pbinns on DSKJLVW7X2PROD with $$_JOB